Global Calciphylaxis Treatment Market - 2022-2029

Global Calciphylaxis Treatment Market - 2022-2029

Market Overview

The global calciphylaxis treatment market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 9.2% during the forecast period (2022-2029).

Calciphylaxis is a rare, painful and life-threatening complication of chronic kidney disease. It occurs when causes calcium deposits form in blood vessels and block blood flow to parts of the skin. This leads to open wounds prone to dangerous or even deadly infections.

Market Dynamics

The global calciphylaxis treatment market growth is driven by advancements in technologies, an increasingly aging population, a rising prevalence of kidney diseases, improving patient awareness, and rising patient healthcare expenditure.

An increasing number of patients with kidney disease across the globe drives the market growth

Chronic kidney disease (CKD) has appeared as one of the most recognized motives of death and suffering in the 21st century. As per the article published in Kidney International Supplements in April 2022, chronic kidney disease is a progressive disease that impacts more than 10% of the general population worldwide, approximately 800 million individuals. Chronic kidney disease mainly occurs in older individuals, racial minorities, women, and people suffering from diabetes mellitus and hypertension. Chronic kidney disease represents an extremely large burden in low- and middle-income countries, which are least equipped to deal with its outcomes. Over the past two decades, it has been one of the few non-communicable diseases associated with deaths.

In addition, as per the article published in Original Research in 2021, the CKD burden is anticipated to constantly increase internationally, driven by the rising prevalence of diabetes, which is the leading cause of CKD globally. This rising burden is predicted to occur in Asia, a region home to more than 4.5 billion people or 60% of the global population. Specifically, in South Asia, diabetes prevalence is estimated to increase by over 150% between 2000 and 2035. With the rising prevalence of kidney disease, there is a major chance of developing calciphylaxis. Resulting in the increasing demand for calciphylaxis treatment worldwide.

The side effects of calciphylaxis treatment will hamper the growth of the market

However, the calciphylaxis treatment shows complications and side effects that can be unexpected and vary from person to person. The Infection might occur in connection with medical procedures, dialysis or surgeries rather than infections from calciphylaxis-caused wounds such as amputation (especially with lesions on hands or feet). This is sometimes necessary when limbs, especially fingers and toes, are damaged beyond repair or recovery. Also, side effects from sodium thiosulfate include nausea, vomiting, fluid balance issues, low blood pressure and blood acidity problems.

COVID-19 Impact Analysis

The COVID‐19 pandemic has blurred the conventional difference between communicable diseases (CD) and non-communicable diseases (NCDs). The indications of COVID‐19 range from an asymptomatic carrier state to fatal multiorgan failure. COVID-19 significantly impacts patients suffering from kidney disease, including acute kidney injury, urinary abnormalities, and tubular function defects. COVID‐19 is common and associated with bad outcomes. Simultaneously, care for patients with existing chronic kidney disease (CKD) has suffered during this pandemic, and those with CKD are considered to have a higher risk for the severity of COVID‐19 symptoms. Widespread lockdowns have affected healthcare delivery to patients with CKD, including those on dialysis or other medication management wait lists. The pandemic has strengthened the need for available home‐based therapies and emphasized the value of teleconsultation and remote monitoring technologies. COVID‐19 has revealed poor emergency preparedness by health systems worldwide.

In addition, more patients with CDK suffer from calciphylaxis due to a lack of treatment during the pandemic. As of 2022, the COVID- 19 situation is recovering. Patients can access healthcare facilities, and the market is growing worldwide.

Segment Analysis

The wound care segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The wound care segment accounts for the largest market share. Regular wound care practices like wound cleansing, debridement, and dressing are important to managing patients with ulcerations from calciphylaxis. Some of the tissue injured by calciphylaxis may require surgery (debridement) for sores to heal. In some circumstances, tissue can be extracted using wet dressings. Antibiotic TreatmentTreatment is part of treating and preventing wound infection.

As per the article published in Advances in Therapy in 2020, the Treatment of pain in wound care can be difficult and should be multimodal and include wound care and modification of risk factors. Analgesic options include nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, and analgesic options targeted at specific patients. Multiple clinical trials are currently underway that are studying targeted therapies for this condition.

In addition, intralesional sodium thiosulfate (250 mg/mL) injected or instilled into areas of clinically active disease has been shown to reduce pain and resolve the purpura of calciphylaxis lesions; pentoxifylline can facilitate vasodilation.

Geographical Analysis

North America region holds the largest market share of the global calciphylaxis treatment market

North America dominates the market for calciphylaxis treatment and is expected to show a similar trend over the forecast period. The market is driven by advanced healthcare infrastructure, the increasing old population and the growing prevalence of kidney disease.

As per the centers for disease control and prevention 2021 data in the United States region, more than 1 in 7, 15% of United States adults or 37 million people, are counted to have CKD. CKD is more familiar in people aged 65 years or older (38%) than in people aged 45–64 years (12%) or 18–44 years (6%). CKD is slightly more expected in women (14%) than in men (12%). The rising number of patients with CDK drives the market for calciphylaxis treatment.

In addition, the market players offer a variety of treatments in the North American region. For instance, the Mayo Clinic provides solutions for calciphylaxis, including dialysis, medications such as warfarin, corticosteroids or iron, calcium or vitamin D supplements, sodium thiosulphate, surgery and others.

Competitive Landscape

The calciphylaxis treatment market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Amgen Inc., Smith & Nephew plc, Medtronics, 3M, BSN Medical, ConvaTec Inc., Sanifit, and Hope Pharmaceuticals, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the calciphylaxis treatment market globally.

ConvaTec Inc.

Overview:

ConvaTec Inc. produces and sells medical supplies. In addition to medical technologies and infusion devices, the company sells wipes, pastes, powders, strips, seals, moist wound dressings, and compression bandages. ConvaTec serves a worldwide clientele.

Product Portfolio:

DuoDERM: It is Adaptable, easy to use and suitable for managing different stages of wound healing and multiple wound types in a care protocol.

The global Calciphylaxis Treatment market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.